Connect with us

Hi, what are you looking for?

Wednesday, Jun 29, 2022
Mugglehead Magazine
Alternative investment news based in Vancouver, B.C.


PharmaCielo ships CBD oil to Brazilian pharmaceutical

This is the second product being developed by the pharmaceutical using PharmaCielo’s APIs

Photo via PharmaCielo

Multinational cannabis producer PharmaCielo Ltd. (TSXV: PCLO) (OTCQX: PCLOF) has shipped pre-commercial quantities of CBD full-spectrum oil to support a Brazilian pharmaceutical’s product development efforts.

On Monday, the firm said it shipped the oil via its Colombia-based subsidiary PharmaCielo Colombia Holdings to an unnamed “well-established” Brazilian pharmaceutical company to support it in developing a full-spectrum product for the local market using PharmaCielo’s API.

The company said that this opens the door to a potential key supply partnership as these products come to market.

This is the second product being developed by the pharmaceutical using PharmaCielo’s APIs. The first one is currently under review by Anvisa and is expected to be approved in the next several months and then launched into the market.

The company also announced that it intends to issue 474,058 common shares at a price of $0.56 each for a total of $265,702.74 in semi-annual interest payments.

Read more: PharmaCielo reports $1.2M in Q1 revenue

Read more: PharmaCielo signs investment agreement to enter Poland

CEO Bill Petron said that with a population of over 200 million and very few Anvisa-approved cannabis products to date, the company expects Brazil to continue to evolve into an important medical cannabis market.

“PharmaCielo is positioned to play an important role as a supplier of choice for cannabis-based APIs in the country, as patient count continues to grow and new products like those in development by our partner, are commercialized,” Petron said.

By entering into relationships with key global pharmaceutical players like our partner in Brazil, we expect to maximize our opportunity to scale PharmaCielo’s API business.”

He added the company is confident that with the progress to date and the current client pipeline, 2022 will be a pivotal year for PharmaCielo and its shareholders.

Company stock went up by 4 per cent to $0.52 on the Canadian Ventures Exchange.


Follow Mugglehead on Twitter

Like Mugglehead on Facebook

Click to comment

Leave a Reply

Your email address will not be published.

You May Also Like

Health and Safety

Science doesn't know yet, but one psychedelic researcher is chasing clues to see if it can


As more medium-to-small producers came into play this year, great weed started hitting legal shelves at fairer prices


Punishments for possession include caning and the death penalty. Despite a global trend of reform, The Fine City remains staunch in its anti-drug stance


While legal weed businesses decry enforcement of their accounts, the platform says it's keeping its all-ages community safe